{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:02:56Z","timestamp":1784588576800,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Surviv"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Determine factors associated with receiving erectile dysfunction (ED) and urinary incontinence (UI) treatment following therapy for clinically localized prostate cancer (PCa).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients diagnosed with PCa (cT1-3N0M0) between 2015 and 2024 who were treated with radical prostatectomy (RP) and\/or radiation therapy (RT) were identified in EPIC Cosmos. Patients receiving hormone monotherapy (HT),\u2009&lt;\u20091 year follow-up, or incomplete data were excluded. ED and UI diagnoses and treatments were captured via CPT and ICD-10 codes. Cox multivariable regression adjusted for clinical and socioeconomic factors to identify treatment predictors, with sensitivity analyses among patients with baseline ED or UI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 90,161 men, 39.29% developed ED, 33.35% received medical ED treatment (EDMT), and 0.99% underwent prosthesis (ST). UI occurred in 20.68% of patients, with 1.4% undergoing surgery (UIT). Black race (HR 1.50,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and prior ED (HR 1.41,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) increased EDMT, while older age (HR 0.66,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), higher social vulnerability (HR 0.85,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and RT-based therapy (RP\u2009+\u2009RT HR 0.75; RT\u2009+\u2009HT HR 0.39; RT HR 0.36; all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) decreased EDMT. Prosthesis use was more likely among Black men (HR 2.03,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), socially vulnerable patients (HR 1.86,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and those with prior ED (HR 2.06,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), but less likely with older age (HR 0.61,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and RT-based therapy (RP\u2009+\u2009RT HR 0.63; RT\u2009+\u2009HT HR 0.18; RT HR 0.14; all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Prior UI (HR 2.08,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and social vulnerability (HR 1.25,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003) increased UIT, whereas RT (HR 0.08,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and RT\u2009+\u2009HT (HR 0.15,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) reduced utilization. These disparities persisted among patients with baseline ED and UI.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite a high prevalence of ED and UI following PCa treatment, surgical intervention remains uncommon (1%). Socioeconomic and clinical factors are significantly associated with treatment patterns, highlighting the need for improved pretreatment counseling and survivorship care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications of Cancer Survivors<\/jats:title>\n                    <jats:p>Medical and surgical interventions for ED and UI are infrequently utilized. The differences in treatment frequency likely reflect not only variations in the underlying frequency, severity and patient preference, but also systemic, racial, and socioeconomic barriers. Prostate cancer survivors should actively advocate for their quality of life by initiating early discussions with their providers regarding all available functional recovery options. Furthermore, establishing equitable, culturally informed, and patient-centered survivorship pathways is vital to ensure all survivors receive the comprehensive care necessary to maximize their long-term outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11764-026-02085-3","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T22:33:45Z","timestamp":1784586825000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prostate cancer survivorship in modern times \u2013 insights into management of erectile dysfunction and urinary incontinence for clinically localized prostate cancer survivors in the United States"],"prefix":"10.1007","author":[{"given":"Rakhsha","family":"Khatri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George E.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas F.","family":"Abdollah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiren V.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"2085_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"CA Cancer J Clin"},{"key":"2085_CR2","unstructured":"AUA Guideline: Part III: principles of radiation and future directions."},{"key":"2085_CR3","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jama.2025.0228","volume":"333","author":"R Raychaudhuri","year":"2025","unstructured":"Raychaudhuri R, Lin DW, Montgomery RB. Prostate cancer: a review. JAMA. 2025;333:1433\u201346. https:\/\/doi.org\/10.1001\/jama.2025.0228.","journal-title":"JAMA"},{"key":"2085_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s11701-025-02496-x","volume":"19","author":"Y Liu","year":"2025","unstructured":"Liu Y, Wang Y, Xiao X, You C, Yu P, Fang Q, et al. Postoperative functional complications and quality of life following robot-assisted prostatectomy and radiotherapy in localized prostate cancer: evidence from a systematic review and meta-analysis. J Robot Surg. 2025;19:314. https:\/\/doi.org\/10.1007\/s11701-025-02496-x.","journal-title":"J Robot Surg"},{"key":"2085_CR5","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s11255-017-1660-5","volume":"49","author":"M Daugherty","year":"2017","unstructured":"Daugherty M, Chelluri R, Bratslavsky G, Byler T. Are we underestimating the rates of incontinence after prostate cancer treatment? Results from NHANES. Int Urol Nephrol. 2017;49:1715\u201321. https:\/\/doi.org\/10.1007\/s11255-017-1660-5.","journal-title":"Int Urol Nephrol"},{"key":"2085_CR6","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1111\/jsm.12647","volume":"11","author":"LR Frederick","year":"2014","unstructured":"Frederick LR, Cakir OO, Arora H, Helfand BT, McVary KT. Undertreatment of erectile dysfunction: claims analysis of 6.2 million patients. J Sex Med. 2014;11:2546\u201353. https:\/\/doi.org\/10.1111\/jsm.12647.","journal-title":"J Sex Med"},{"key":"2085_CR7","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/bco2.342","volume":"5","author":"O Adesanya","year":"2024","unstructured":"Adesanya O, Rojanasarot S, McGovern AM, Burnett AL. Racial and socioeconomic disparities in surgical care for post-prostate cancer treatment complications: a nationwide Medicare-based analysis. BJUI Compass. 2024;5:564\u201375. https:\/\/doi.org\/10.1002\/bco2.342.","journal-title":"BJUI Compass"},{"key":"2085_CR8","doi-asserted-by":"publisher","first-page":"EVIDoa2300018","DOI":"10.1056\/EVIDoa2300018","volume":"2","author":"JL Donovan","year":"2023","unstructured":"Donovan JL, Hamdy FC, Lane JA, Young GJ, Metcalfe C, Walsh EI, et al. Patient-reported outcomes 12 years after localized prostate cancer treatment. NEJM Evid Mass Med Soc. 2023;2:EVIDoa2300018. https:\/\/doi.org\/10.1056\/EVIDoa2300018.","journal-title":"NEJM Evid Mass Med Soc"},{"key":"2085_CR9","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","volume":"375","author":"JL Donovan","year":"2016","unstructured":"Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. New England J Med Mass Med Soc. 2016;375:1425\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1606221.","journal-title":"New England J Med Mass Med Soc"},{"key":"2085_CR10","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1055\/s-0041-1731004","volume":"05","author":"Y Tarabichi","year":"2021","unstructured":"Tarabichi Y, Frees A, Honeywell S, Huang C, Naidech AM, Moore JH, et al. The cosmos collaborative: a vendor-facilitated electronic health record data aggregation platform. ACI Open Georg Thieme Verlag KG. 2021;05:e36-46. https:\/\/doi.org\/10.1055\/s-0041-1731004.","journal-title":"ACI Open Georg Thieme Verlag KG"},{"key":"2085_CR11","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","volume":"4","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, G\u00f8tzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLOS Med Public Library Sci. 2007;4:e297. https:\/\/doi.org\/10.1371\/journal.pmed.0040297.","journal-title":"PLOS Med Public Library Sci"},{"key":"2085_CR12","unstructured":"CDC. Social Vulnerability Index [Internet]. Place and health - Geospatial Research, Analysis, and Services Program (GRASP). 2024 [cited 2025 Sept 28]. https:\/\/www.atsdr.cdc.gov\/place-health\/php\/svi\/index.html. Accessed 28 Sept 2025"},{"key":"2085_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/pcan.2016.43","volume":"20","author":"B Hager","year":"2017","unstructured":"Hager B, Kraywinkel K, Keck B, Katalinic A, Meyer M, Zeissig SR, et al. Increasing use of radical prostatectomy for locally advanced prostate cancer in the USA and Germany: a comparative population-based study. Prostate Cancer Prostatic Dis. 2017;20:61\u20136. https:\/\/doi.org\/10.1038\/pcan.2016.43.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2085_CR14","doi-asserted-by":"publisher","first-page":"3787","DOI":"10.1002\/cncr.34433","volume":"128","author":"JW Lillard","year":"2022","unstructured":"Lillard JW, Moses KA, Mahal BA, George DJ. Racial disparities in Black men with prostate cancer: a literature review. Cancer. 2022;128:3787\u201395. https:\/\/doi.org\/10.1002\/cncr.34433.","journal-title":"Cancer"},{"key":"2085_CR15","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.jsxm.2020.02.022","volume":"17","author":"P Bajic","year":"2020","unstructured":"Bajic P, Patel PM, Nelson MH, Dornbier RA, Kirshenbaum EJ, Baker MS, et al. Penile prosthesis implantation and timing disparities after radical prostatectomy: results from a statewide claims database. J Sex Med. 2020;17:1175\u201381. https:\/\/doi.org\/10.1016\/j.jsxm.2020.02.022.","journal-title":"J Sex Med"},{"key":"2085_CR16","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1097\/JU.0000000000000618","volume":"203","author":"M Nelson","year":"2020","unstructured":"Nelson M, Dornbier R, Kirshenbaum E, Eguia E, Sweigert P, Baker M, et al. Use of surgery for post-prostatectomy incontinence. J Urol. 2020;203:786\u201391. https:\/\/doi.org\/10.1097\/JU.0000000000000618.","journal-title":"J Urol"},{"key":"2085_CR17","doi-asserted-by":"publisher","unstructured":"Carlisle MN, Li KD, Jarosek SL, Faris AR, Patel HV, Samuel L. Washington III, et al. Rural-urban differences and socioeconomic disparities in long-term urinary adverse events after prostate cancer treatment. urology practice [Internet]. Wolters KluwerPhiladelphia, PA; 2025 [cited 2025 June 16]; https:\/\/doi.org\/10.1097\/UPJ.0000000000000837","DOI":"10.1097\/UPJ.0000000000000837"},{"key":"2085_CR18","doi-asserted-by":"publisher","first-page":"e2410162","DOI":"10.1001\/jamanetworkopen.2024.10162","volume":"7","author":"RR Sekar","year":"2024","unstructured":"Sekar RR, Herrel LA, Stensland KD. Social determinants of health and the availability of cancer clinical trials in the United States. JAMA Netw Open. 2024;7:e2410162. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.10162.","journal-title":"JAMA Netw Open"},{"key":"2085_CR19","doi-asserted-by":"publisher","first-page":"e2139593","DOI":"10.1001\/jamanetworkopen.2021.39593","volume":"4","author":"E Cheng","year":"2021","unstructured":"Cheng E, Soulos PR, Irwin ML, Cespedes Feliciano EM, Presley CJ, Fuchs CS, et al. Neighborhood and individual socioeconomic disadvantage and survival among patients with nonmetastatic common cancers. JAMA Netw Open. 2021;4:e2139593. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.39593.","journal-title":"JAMA Netw Open"},{"key":"2085_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.eururo.2008.03.026","volume":"55","author":"M Pinkawa","year":"2009","unstructured":"Pinkawa M, Gagel B, Piroth MD, Fischedick K, Asadpour B, Kehl M, et al. Erectile dysfunction after external beam radiotherapy for prostate cancer. Eur Urol. 2009;55:227\u201334. https:\/\/doi.org\/10.1016\/j.eururo.2008.03.026.","journal-title":"Eur Urol"},{"key":"2085_CR21","doi-asserted-by":"publisher","first-page":"S883","DOI":"10.21037\/tau.2017.07.05","volume":"6","author":"P Dadhich","year":"2017","unstructured":"Dadhich P, Hockenberry M, Kirby EW, Lipshultz L. Penile prosthesis in the management of erectile dysfunction following cancer therapy. Transl Androl Urol. 2017;6:S883\u20139. https:\/\/doi.org\/10.21037\/tau.2017.07.05.","journal-title":"Transl Androl Urol"},{"key":"2085_CR22","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/NEJMoa1209978","volume":"368","author":"MJ Resnick","year":"2013","unstructured":"Resnick MJ, Koyama T, Fan K-H, Albertsen PC, Goodman M, Hamilton AS, et al. Long-term functional outcomes after treatment for localized prostate cancer. New England J Med Massachusetts Med Soc. 2013;368:436\u201345. https:\/\/doi.org\/10.1056\/NEJMoa1209978.","journal-title":"New England J Med Massachusetts Med Soc"},{"key":"2085_CR23","doi-asserted-by":"publisher","unstructured":"Roy S, Grimes S, Morgan SC, Eapen L, Malone J, Craig J, et al. Patient-reported outcomes from a phase 3 randomized controlled trial exploring optimal sequencing of short-term androgen deprivation therapy with prostate radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys. Elsevier; 2021;110:1101\u201313. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.01.032","DOI":"10.1016\/j.ijrobp.2021.01.032"},{"key":"2085_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.05.014","author":"KD Li","year":"2025","unstructured":"Li KD, Carlisle MN, Jarosek S, Patel HV, Faris A, Elliott SP, et al. Evolving risk of urinary adverse events across localized prostate cancer treatments: a propensity-weighted analysis of surveillance, epidemiology and end results-Medicare data. Eur Urol. 2025. https:\/\/doi.org\/10.1016\/j.eururo.2025.05.014.","journal-title":"Eur Urol"}],"container-title":["Journal of Cancer Survivorship"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-026-02085-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11764-026-02085-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-026-02085-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T22:33:46Z","timestamp":1784586826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11764-026-02085-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":24,"alternative-id":["2085"],"URL":"https:\/\/doi.org\/10.1007\/s11764-026-02085-3","relation":{},"ISSN":["1932-2259","1932-2267"],"issn-type":[{"value":"1932-2259","type":"print"},{"value":"1932-2267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"16 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}